Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MAZ Double Nickase Plasmid (h): sc-403775-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MAZ Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MAZ Double Nickase Plasmid (h) and MAZ Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MAZ. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MAZ Antibody (133.7): sc-130915
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAZ Double Nickase Plasmid (h) | sc-403775-NIC | 20 µg | $410.00 | |||
MAZ Double Nickase Plasmid (h2) | sc-403775-NIC-2 | 20 µg | $410.00 |
MAZ (Myc-associated zinc finger protein) is a GC-rich DNA-binding transcription factor that recognizes GA box elements and modulates RNA polymerase II–dependent transcription at promoter-proximal regions. It participates in regulation of cell-cycle progression, differentiation programs, and stress-responsive gene expression, and can influence chromatin architecture through interactions with transcriptional cofactors. MAZ has been linked to control of oncogene and cytokine expression, including MYC-associated transcriptional networks, making it relevant to studies of proliferation and inflammatory signaling. Dysregulated MAZ activity or altered MAZ-controlled promoter usage has been observed across multiple cancer contexts and is also studied in relation to transcriptional rewiring in metabolic and immune pathways.
MAZ Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MAZ locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MAZ. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MAZ function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MAZ-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.